Overview

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Status:
Not yet recruiting
Trial end date:
2026-08-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Rigel Pharmaceuticals